服用 elexacaftor/tezacaftor/ivacaftor (ETI) 时,"健康 "意味着什么?定性研究。

IF 5.4 2区 医学 Q1 RESPIRATORY SYSTEM Journal of Cystic Fibrosis Pub Date : 2024-11-21 DOI:10.1016/j.jcf.2024.11.003
Robin S Everhart, Emma McWilliams, Jill Maggs, Gregory S Sawicki, Takeera Sconiers, Kyle Smith, Dana Yablon, Jennifer Butcher, Michelle Prickett, Callie Bacon, Andrea Goodman, Alex H Gifford, Nicole Mayer-Hamblett, David P Nichols, Kristin A Riekert
{"title":"服用 elexacaftor/tezacaftor/ivacaftor (ETI) 时,\"健康 \"意味着什么?定性研究。","authors":"Robin S Everhart, Emma McWilliams, Jill Maggs, Gregory S Sawicki, Takeera Sconiers, Kyle Smith, Dana Yablon, Jennifer Butcher, Michelle Prickett, Callie Bacon, Andrea Goodman, Alex H Gifford, Nicole Mayer-Hamblett, David P Nichols, Kristin A Riekert","doi":"10.1016/j.jcf.2024.11.003","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Elexacaftor/tezacaftor/ivacaftor (ETI) has profoundly affected the health and lives of many people with CF (pwCF). The rapid change in health for pwCF taking ETI provided them an opportunity to reflect on what \"being healthy\" means. The goal of this secondary analysis was to document changes in the health and well-being of pwCF after starting ETI, beyond the expected physical benefits.</p><p><strong>Methods: </strong>The Qualitative Understanding of Experiences with the SIMPLIFY Trial (QUEST) study evaluated pwCF's experiences on ETI, including participation in a withdrawal study, treatment burden, and experiences of health. Two sixty-minute interviews were conducted approximately four months apart, audio-recorded and transcribed. A phenomenological approach was used to identify text of interest and create a formal codebook.</p><p><strong>Results: </strong>Ninety-one pwCF (mean age=27.8 years; range 14-67; 51 % male) and 23 caregivers of the teenagers completed at least one interview. Beyond the expected benefits of ETI, four themes were identified: (1) Night and Day Change in Health, (2) Reduced Cognitive Burden, (3) Shifting to Managing Overall Wellness and Co-Morbidities, and (4) Social/Self Identity Changes.</p><p><strong>Conclusion: </strong>ETI has raised pwCF's expectations for their health and well-being. Current symptom and QOL measures may no longer capture the less perceptible ways pwCF on ETI experience changes in symptoms or health. CF care may need to adapt to focus more on general health, managing other comorbidities, and planning for the future.</p>","PeriodicalId":15452,"journal":{"name":"Journal of Cystic Fibrosis","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"What does it mean to be \\\"healthy\\\" when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study.\",\"authors\":\"Robin S Everhart, Emma McWilliams, Jill Maggs, Gregory S Sawicki, Takeera Sconiers, Kyle Smith, Dana Yablon, Jennifer Butcher, Michelle Prickett, Callie Bacon, Andrea Goodman, Alex H Gifford, Nicole Mayer-Hamblett, David P Nichols, Kristin A Riekert\",\"doi\":\"10.1016/j.jcf.2024.11.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Elexacaftor/tezacaftor/ivacaftor (ETI) has profoundly affected the health and lives of many people with CF (pwCF). The rapid change in health for pwCF taking ETI provided them an opportunity to reflect on what \\\"being healthy\\\" means. The goal of this secondary analysis was to document changes in the health and well-being of pwCF after starting ETI, beyond the expected physical benefits.</p><p><strong>Methods: </strong>The Qualitative Understanding of Experiences with the SIMPLIFY Trial (QUEST) study evaluated pwCF's experiences on ETI, including participation in a withdrawal study, treatment burden, and experiences of health. Two sixty-minute interviews were conducted approximately four months apart, audio-recorded and transcribed. A phenomenological approach was used to identify text of interest and create a formal codebook.</p><p><strong>Results: </strong>Ninety-one pwCF (mean age=27.8 years; range 14-67; 51 % male) and 23 caregivers of the teenagers completed at least one interview. Beyond the expected benefits of ETI, four themes were identified: (1) Night and Day Change in Health, (2) Reduced Cognitive Burden, (3) Shifting to Managing Overall Wellness and Co-Morbidities, and (4) Social/Self Identity Changes.</p><p><strong>Conclusion: </strong>ETI has raised pwCF's expectations for their health and well-being. Current symptom and QOL measures may no longer capture the less perceptible ways pwCF on ETI experience changes in symptoms or health. CF care may need to adapt to focus more on general health, managing other comorbidities, and planning for the future.</p>\",\"PeriodicalId\":15452,\"journal\":{\"name\":\"Journal of Cystic Fibrosis\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2024-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cystic Fibrosis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jcf.2024.11.003\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cystic Fibrosis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jcf.2024.11.003","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

背景:Elexacaftor/tezacaftor/ivacaftor (ETI) 对许多 CF 患者(pwCF)的健康和生活产生了深远的影响。服用 ETI 的 CF 患者健康状况的迅速变化为他们提供了一个反思 "健康 "含义的机会。本二次分析的目的是记录 pwCF 在开始服用 ETI 后,除了预期的身体益处外,在健康和福祉方面发生的变化:对 SIMPLIFY 试验经历的定性了解 (QUEST) 研究评估了 pwCF 在 ETI 上的经历,包括参与退出研究、治疗负担和健康经历。我们进行了两次 60 分钟的访谈,每次相隔约四个月,并进行了录音和转录。采用现象学方法识别感兴趣的文本,并创建正式的编码手册:91 名儿童和青少年(平均年龄=27.8 岁;14-67 岁不等;51% 为男性)和 23 名青少年的照顾者至少完成了一次访谈。除了 ETI 的预期益处外,还确定了四个主题:(1) 日夜改变健康状况,(2) 减轻认知负担,(3) 转向管理整体健康和并发症,以及 (4) 社会/自我身份改变:结论:ETI 提高了残疾人对其健康和福祉的期望。目前的症状和 QOL 测量方法可能已无法捕捉到接受 ETI 的患者在症状或健康方面不易察觉的变化。CF护理可能需要进行调整,以更加关注总体健康、管理其他合并症和规划未来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
What does it mean to be "healthy" when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study.

Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has profoundly affected the health and lives of many people with CF (pwCF). The rapid change in health for pwCF taking ETI provided them an opportunity to reflect on what "being healthy" means. The goal of this secondary analysis was to document changes in the health and well-being of pwCF after starting ETI, beyond the expected physical benefits.

Methods: The Qualitative Understanding of Experiences with the SIMPLIFY Trial (QUEST) study evaluated pwCF's experiences on ETI, including participation in a withdrawal study, treatment burden, and experiences of health. Two sixty-minute interviews were conducted approximately four months apart, audio-recorded and transcribed. A phenomenological approach was used to identify text of interest and create a formal codebook.

Results: Ninety-one pwCF (mean age=27.8 years; range 14-67; 51 % male) and 23 caregivers of the teenagers completed at least one interview. Beyond the expected benefits of ETI, four themes were identified: (1) Night and Day Change in Health, (2) Reduced Cognitive Burden, (3) Shifting to Managing Overall Wellness and Co-Morbidities, and (4) Social/Self Identity Changes.

Conclusion: ETI has raised pwCF's expectations for their health and well-being. Current symptom and QOL measures may no longer capture the less perceptible ways pwCF on ETI experience changes in symptoms or health. CF care may need to adapt to focus more on general health, managing other comorbidities, and planning for the future.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Cystic Fibrosis
Journal of Cystic Fibrosis 医学-呼吸系统
CiteScore
10.10
自引率
13.50%
发文量
1361
审稿时长
50 days
期刊介绍: The Journal of Cystic Fibrosis is the official journal of the European Cystic Fibrosis Society. The journal is devoted to promoting the research and treatment of cystic fibrosis. To this end the journal publishes original scientific articles, editorials, case reports, short communications and other information relevant to cystic fibrosis. The journal also publishes news and articles concerning the activities and policies of the ECFS as well as those of other societies related the ECFS.
期刊最新文献
Elexacaftor/tezacaftor/ivacaftor and mental health: A workshop report from the Cystic Fibrosis Foundation's Prioritizing Research in Mental Health working group. Coping and learning to Manage Stress with cystic fibrosis (CALM): A multisite telehealth randomized controlled trial to reduce depression and anxiety symptoms in adults with cystic fibrosis. Bridging the gap: Challenging lung infections and clinical trial development in cystic fibrosis. Impact of elexacaftor/tezacaftor/ivacaftor on utilization of routine therapies in cystic fibrosis: Danish nationwide register study. What does it mean to be "healthy" when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1